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A B S T R A C T
Background: Anxiety disorders have been related to cardiovascular diseases via low-grade inflammation, but
longitudinal studies on the association between generalized anxiety disorder (GAD) and inflammatory bio-
markers are sparse. Furthermore, no studies have examined the association between GAD and the “cardio-
protective” adipocytokine adiponectin in this context so far.
Methods: In a Swiss population-based sample of 2,415 adults participating in baseline and follow-up exams
(mean follow-up duration=5.5 years), we diagnosed a total of 55 persons (2.3%) with GAD using a validated
semi-structured psychiatric interview. We prospectively examined the relation between GAD and circulating
levels of inflammatory biomarkers (i.e., C-reactive protein, interleukin (IL)-1β, IL-6, tumor necrosis factor-α, and
adiponectin), in linear regression models, statistically controlled for the baseline inflammatory marker, socio-
economic status, cardiovascular risk factors, health behaviors, and psychiatric disorders.
Results: Compared to those without GAD, individuals with GAD had lower IL-6 (β=-0.249, 95%-CI -0.493-
(-0.004), p=0.046), and adiponectin (β=-0.264, 95%-CI -0.482-(-0.045), p=0.018) levels at follow-up after
adjustment for all covariates. Moreover, GAD was unrelated to several other inflammatory measures.
Conclusion: Individuals with GAD do not seem to exhibit chronic low-grade inflammation, suggesting different
underlying biobehavioral mechanisms to those from other anxiety disorders. Low adiponectin levels may be
linked to symptoms of GAD through brain areas directly involved in the processing of fear and anxiety.
1. Introduction
The link between anxiety disorders, including Generalized Anxiety
Disorder (GAD), and an increased risk of incident cardiovascular dis-
ease (CVD) might be related to inflammatory changes such as C-reactive
protein (CRP), interleukin (IL)-6, tumor necrosis factor (TNF)-α
(Kaptoge et al., 2014), and the “cardio-protective” adiponectin (Li and
Wu, 2012). Proinflammatory changes are linked to altered hypotha-
lamic-pituitary (HPA) axis responses caused by chronic stress as
represented by persistent anxiety states, thereby increasing the risk for
excessive systemic inflammation (Mehta and Binder, 2012). In this
context, adiponectin might not only operate as a cardio-protective
factor (Li and Wu, 2012; Garfinkel et al.; 2014; Zhang et al., 2017). The
latter is derived mainly from white adipose tissue, a major endocrine
organ that secretes adipokines involved in systemic inflammation of
cardiovascular, metabolic and autoimmune diseases. Different isoforms
(polymers) of adiponectin exist in the blood, which may also differ in
their binding activity to membrane receptors and signal distinct effects
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in the cardiovascular system. Low plasma levels of adiponectin were
associated with obesity, type 2 diabetes, and coronary artery disease
(CAD) compared to healthy individuals. Additionally, hypoadiponecti-
nemia showed a higher risk and prevalence of obesity-related diabetic
and cardiovascular disorders (Li and Wu, 2012). While the beneficial
role of adiponectin on cardiovascular functions and energy homeostasis
via directly modulating IL-6 has been known for some time, more re-
cent studies indicate that higher levels of adiponectin may also appear
as an inducer of inflammatory factors aggravating inflammatory re-
sponse in autoimmune diseases (Li and Wu, 2012). However, further
research is needed to investigate the pleiotropic features of adiponectin
better and to find out if such an interaction between adiponectin and IL-
6 might also apply to GAD.
IL-6 is one of the best examined proinflammatory cytokines with
prototypical features contributing to cell proliferation and differentia-
tion, as well as to host defense. In response to acute infections or tissue
damage, IL-6 is produced by immune-mediated cells like macrophages
and monocytes. IL-6 is also generated by endothelial cells, by adipo-
cytes like adiponectin, mesenchymal cells, fibroblasts, and numerous
other cells in response to miscellaneous stimuli (Tanaka et al., 2016).
„IL-6 signaling is mediated by building a complex of IL-6, the trans-
membrane IL-6 receptor (mIL-6R) or with soluble forms of IL-6R (sIL-
6R), and the signal-transducing subunit molecule gp130.“
(Tanaka et al., 2016) These pathways help to explain the pleiotropic
functions of IL-6. “The control of IL-6 signaling is regulated through the
induction of suppressor molecules after activation of the IL-6 pathways
as well as through the presence of sIL-6R and gp130 forms in the blood.
Vice versa, an overproduction of IL-6 and a dysregulation of the IL-6
signaling pathways can result in inflammatory and autoimmune dis-
orders suggesting that IL-6 plays a significant role in the human cyto-
kine network.“ (Tanaka et al., 2016) The ubiquitary involvement of IL-6
in immune function may also have a potential impact in anxiety states.
In a recent systematic review and meta-analysis on peripheral cy-
tokines in GAD, CRP was found to be significantly higher in individuals
with GAD compared to controls (Costello et al., 2019). However, only
CRP data were sufficient for the meta-analysis and 5 of 14 studies
meeting inclusion criteria for review showed no group differences in
any cytokine measured (Costello et al., 2019). There was some in-
dication for higher IL-6 and TNF-α in individuals with versus without
GAD from cross-sectional analyses, although most studies had small
sample sizes and did not sufficiently adjust for confounders. We found
anxiety disorders associated with lower high sensitive (hs)-CRP cross-
sectionally, but the association was probably attributed to the low body
mass index of participants with anxiety disorders (Glaus et al., 2014).
The only longitudinal study on the association between GAD and CRP
cited was in adolescents (Costello et al., 2019), whereas IL-1β, IL-6 and
TNF-α have not been studied longitudinally so far in GAD according to
the review (Costello et al., 2019). The available data let the authors
conclude that high heterogeneity across studies means that findings
should be interpreted with caution and that further longitudinal studies
are needed (Costello et al., 2019). A more recent longitudinal cohort
study not included in that meta-analysis found no association between
GAD and low-grade inflammation in terms of CRP and IL-6
(Lamers et al., 2019). Based on our own cohort data, we also found no
prospective association between current or remitted GAD with hs-CRP,
IL-6, and TNF-α (Glaus et al., 2018). However, the division in two ca-
tegories of anxiety reduced statistical power, and we also did not con-
trol for latent classes of psychiatric disorders systematically.
Therefore, we aimed to extend our prospective investigation on
changes in circulating markers of low-grade inflammation among in-
dividuals with lifetime GAD compared to those without in a large
community-based sample, while taking into account several health-re-
lated covariates commonly associated with both inflammation and CVD
risk. The novelty of our work are measurements on adiponectin and IL-
1β, which have not been examined in this context so far. We hy-
pothesized that individuals with GAD will show subsequent increases of
CRP, IL-1β, IL-6 and TNF-α on the one hand, and a decrease in adi-
ponectin on the other (Kaptoge et al., 2014).
2. Material and Methods
The data for the present study are derived from the
CoLaus|PsyCoLaus cohort study (Glaus et al., 2018) implemented to
better understand the relationship between psychiatric disorders and
CVD. Information on mental disorders at baseline was collected using
the semi-structured Diagnostic Interview for Genetic Studies completed
with questions from the Schedule for Affective Disorders and Schizo-
phrenia - Lifetime and Anxiety disorder version to extend the anxiety
sections. The follow-up took place 5.5 years (2009-2012) after the
baseline exam.
A total of 2,415 participants were assessed twice (at the somatic
baseline and follow-up exams) for inflammatory markers including hs-
CRP, IL-1β, IL-6, TNF-α, and adiponectin, and had no missing in-
formation on covariates. Subjects with hs-CRP >10 mg/L, indicative of
acute infection, were excluded from the analyses.
For statistical analyses, inflammatory measures were log10-trans-
formed and then z-standardized to normalize distributions. In order to
classify distinct patterns of DSM-IV psychiatric comorbidity we con-
ducted a latent class analysis. Associations between lifetime GAD at
baseline and levels of inflammatory markers at follow-up serially ad-
justed for the respective levels at baseline and additional covariates
including classes of psychiatric disorders were determined using mul-
tiple linear regression models.
3. Results
On average, participants were 50 years old and 47% were male. A
total of 2.3% (n=55) of the participants reported lifetime GAD at
baseline (mean duration of GAD±SD: 14.5 years± 16.7 (range: 1-
61)). A large proportion of the participants were physically inactive
(39%), and were prior or present smokers (61%). The comparison be-
tween participants with versus those without GAD showed no sig-
nificant difference in demographics, cardiovascular risk factors or
health behaviors. However, individuals with GAD were more frequently
female and reported more concomitant anxiety and mood disorders
(Table 1). Participants with GAD showed significantly lower IL-6 and
adiponectin levels at follow-up than those without GAD after adjust-
ment for all covariates (Table 2). In contrast, levels of hs-CRP, IL-1β,
and TNF-α at follow-up did not significantly differ between groups.
4. Discussion
In this Swiss community-based sample of 2,415 adults we found a
significant decrease in adiponectin and IL-6 over time in individuals
with GAD compared to those without, whereas IL-1β and TNF-α, but
also hs-CRP showed no significant group differences. With a prevalence
of 2.3% and a women-to-men ratio of 2:1 for GAD, our sample may be
considered to be representative of the community (Wittchen et al.,
2002).
This is the first study that examined the prospective association of
GAD with adiponectin and IL-1β. The work is novel in showing de-
creased levels of adiponectin over time in individuals with GAD com-
pared to those without. No definite interpretation can be made as to
whether high adiponectin exert pro- or anti-inflammatory effects
(Kaptoge et al., 2014). Low adiponectin levels have been associated
with a higher risk for coronary artery disease, with obesity-related type
2 diabetes, and also with obesity compared to healthy individuals di-
rectly affecting IL-6 (Kaptoge et al., 2014). However, IL-6 showed a
decrease over time, whereas the other inflammatory markers did not
significantly change in our study. A parsimonious interpretation of
these findings is that GAD does not seem to be associated with an in-
crease in low-grade inflammation over time in terms of major
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inflammatory biomarkers of an increased CVD risk.
Adiponectin might have another function in GAD, which might not
become apparent in inflammatory and autoimmune diseases, perhaps
due to a different genetic allocation of adiponectin receptors in the
context of fear heredity. Indeed, a deficiency of adiponectin in GAD
might be referred to functional magnetic resonance imaging (fMRI)
studies, which support the hypothesis, that adiponectin might alleviate
fear extinction (Garfinkel et al., 2014; Vuong et al. 2020; Zhang et al.,
2017) through the adiponectin receptor 2 (AdipoR2) (Zhang et al.,
2017). AdipoR1 and AdipoR2 are primarily allotted in the hypotha-
lamus and hippocampus (Garfinkel et al., 2014) and are also closely
associated with anxiety modulating the hypothalamic-pituitary axis
(Vuong et al. 2020). These findings are also supported by a recent meta-
analysis, which found an inverse association between anxiety and adi-
ponectin levels in obsessive-compulsive disorder, phobic anxiety, panic
disorder, antenatal anxiety, and posttraumatic anxiety stress disorder
(Vuong et al. 2020). Thus, low adiponectin levels might be linked to
symptoms of anxiety through brain areas directly (such as the pre-
frontal cortex, amygdala, insula, and hippocampus) involved in the
processing of fear and anxiety (Garfinkel et al.; 2014, Vuong et al. 2020;
Zhang et al., 2017).
Three cross-sectional studies found increased IL-6 in GAD, one in
Table 1
Baseline characteristics in the whole sample and according to presence or absence of generalized anxiety disorder (GAD) at baseline (n = 2,415).
All(n = 2,415) GAD(n = 55, 2.3%) No GAD(n = 2,360, 97.7%) Statistics p value
Socio-demographic characteristics
Age, years 50.0±8.8 (35.0 - 66.6) 52.1±8.4 (37.3 - 65.7) 49.9± 8.9 (35.0 - 66.6) t=-1.8 0.077
Gender, male / female 47% / 53 % 33% / 67% 47% / 53% χ2=4.4 0.036
Socioeconomic statusa 3.4± 1.3 (1.0 - 5.0) 3.3± 1.3 (1.0 - 5.0) 3.4±1.3 (1.0 - 5.0) t=0.9 0.359
Length of follow-upb, years 5.5± 0.4 (4.8 - 8.5) 5.5± 0.4 (5.0 - 7.8) 5.5±0.4 (4.8 - 8.5) t=0.4 0.679
Cardio-metabolic risk factors
Systolic blood pressure, mmHg 124.5± 16.0 (81.5 - 219.0) 122.4± 16.4 (86.5 - 157.5) 124.6± 16.0 (81.5 - 219.0) t=1.0 0.316
Body mass index, kg/m² 25.1±4.1 (15.7 - 59.2) 25.4±3.6 (19.4 – 34.8) 25.1± 4.1 (15.7 - 59.2) t=-0.5 0.594
Glucose, fasting state, mmol/L 5.5± 0.9 (0.3 - 21.2) 5.6± 1.2 (4.2 - 11.7) 5.4±0.9 (0.3 - 21.2) t=-1.3 0.182
















Physical inactivityc 39% 35% 39% χ2=0.6 0.458
Psychiatric disorders, DSM-IV
Healthy and depressive disorder class 78% 33% 79% χ22=97.4 <0.001
Anxiety and mood disorder class 16% 65% 15%
Substance disorder class 6% 2% 6%
Data are given as mean± standard deviation (range) or percentage values. χ2/t: comparison with subjects with no GAD based on χ2 tests (categorical variables) / t-
tests (continuous variables).
LDL, low-density lipoprotein; HDL, high-density lipoprotein; DSM, Diagnostic and Statistical Manual of Mental Disorders.
a A value of “3” represents a socioeconomic status of III (middle class) on the Hollingshead Scale.
b Duration between somatic evaluation at baseline and somatic evaluation at follow-up.
c Physically inactive if less than 20 minutes twice a week.
Table 2
Associations between lifetime General Anxiety Disorder status at baseline and inflammatory measures at follow-up (n = 2,415).
All participants General Anxiety Disorder at baseline
(n = 2,415) Yes(n = 55, 2.3%) No(n = 2,360, 97.7%) Crude Model 1 Model 2
Median (IQR) Median (IQR) Median (IQR) t p βa 95CI βa 95CI
Inflammatory markers at baseline
Hs-CRP, mg/l 1.0 (0.5-2.1) 1.2 (0.6-2.7) 1.1 (0.5-2.1) -0.8 0.406
Interleukin-1β, pg/ml 0.4 (0.1-2.0) 0.3 (0.1-3.8) 0.4 (0.1-2.0) -0.3 0.749
Interleukin-6, pg/ml 1.2 (0.5 -3.0) 1.3 (0.7-3.2) 1.2 (0.5-3.0) -0.8 0.406
TNF-α, pg/ml 2.7 (1.7-4.4) 3.3 (2.0-5.0) 2.7 (1.7-4.3) -1.4 0.159
Adiponectin, mg/l 8.3 (5.2-12.8) 8.3 (5.4-14.4) 8.3 (5.2-12.7) -0.7 0.468
Inflammatory markers at follow-up
Hs-CRP, mg/l 1.1 (0.6-2.3) 1.4 (0.7-2.3) 1.1 (0.6-2.3) -0.9 0.386 0.040 -0.175, 0.256 0.028 -0.190, 0.245
Interleukin-1β, pg/ml 0.7 (0.1-2.6) 1.0 (0.1-4.3) 0.7 (0.1-2.5) -0.9 0.375 0.109 -0.124, 0.342 0.107 -0.131, 0.345
Interleukin-6, pg/ml 2.4 (0.9-8.2) 1.7 (0.7-5.5) 2.5 (0.9-8.3) 1.3 0.190 -0.221 -0.460, 0.018 -0.249* -0.493, -0.004
TNF-α, pg/ml 4.6 (2.4-8.0) 4.6 (2.7-8.7) 4.6 (2.4-8.0) -0.2 0.866 -0.043 -0.288, 0.202 -0.099 -0.349, 0.152
Adiponectin, mg/l 3.8 (2.4-6.1) 3.3 (1.9-5.6) 3.8 (2.4-6.1) 1.2 0.218 -0.278* -0.494, -0.062 -0.264* -0.482, -0.045
Values for inflammatory measures were log-transformed and standardized and are given as medians (interquartile ranges).
t: comparison of subjects with versus without GAD based on t-tests.
GAD, General Anxiety Disorder; hs-CRP, high-sensitive C-reactive protein; TNF, tumor necrosis factor; IQR, interquartile range; 95CI, 95% confidence intervals.
Model 1 = adjusted for the corresponding inflammatory marker at baseline, length of follow-up, and socio-demographic variables (age, gender, socioeconomic
status).
Model 2 = Model 1 + behavioral cardiovascular risk factors (physical activity, smoking status), physical cardiovascular risk factors (body mass index, glucose level,
systolic blood pressure, low density lipoprotein/high density lipoprotein ratio) at baseline, and Diagnostic and Statistical Manual of Mental Disorders (DSM)-IV
classes.
a Multiple regression with log-transformed and standardized cytokine or hs-CRP or adiponectin.
⁎ p<0.05.
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saliva, all with less rigorous adjustment for potentially confounding
variables than in our study (Costello et al., 2019). The only two long-
itudinal studies found no association between GAD and IL-6
(Glaus et al., 2018; Lamers et al., 2019), whereas we found decreased
IL-6 levels in GAD only after systematically controlling for all psy-
chiatric classes in the final statistical model. Therefore, based on the
currently available data it would be premature to make a final judg-
ment about an independent relationship of GAD with increased or de-
creased levels of IL-6.
To sum up, this study showed a decrease over time in both adipo-
nectin and IL-6 in individuals with GAD compared to their counterparts
implicating that chronic low-grade inflammation is unlikely a plausible
link between GAD and incident CVD. Future longitudinal studies should
explore alternative mechanisms underlying the potential association
between GAD and the CVD risk.
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